Cupric Chloride
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Cupric Chloride
- Cupric Chloride: From an Unspecified Original Indication to Primary Release Disorder of Platelets
Cupric Chloride: From an Unspecified Original Indication to Primary Release Disorder of Platelets
One-Sentence Summary
Cupric Chloride is an essential trace element, registered in South Africa as a component of the infusion product Addaven. The registration data does not record an approved indication. The TxGNN model predicts it may be effective for primary release disorder of platelets, but 0 clinical trials and 0 publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Copper is an essential trace element and a cofactor for enzymes such as lysyl oxidase and ceruloplasmin. Its best-known clinical effect is that deficiency causes anaemia and neutropenia.
Nothing in the available data links cupric chloride to platelet granule secretion or release pathways. The high score (0.993) is a knowledge-graph prediction. It may reflect graph-neighbourhood similarity rather than biology, and the evidence does not yet support it as a mechanistically grounded hypothesis.
The model’s other top predictions have the same weakness:
- Pseudo-von Willebrand disease (99.25%) is caused by gain-of-function variants in the platelet GPIb-alpha receptor gene (GP1BA). A trace-element supplement would not be expected to correct a genetic receptor defect.
- Thrombocytopenia due to immune destruction (99.02%) involves autoantibody-mediated platelet clearance. Copper deficiency can cause cytopenias, but that is a nutritional mechanism, not immune destruction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 49/24/0996 | Addaven | Infusion | Not stated in registration data |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (L5). There are no trials or publications, and the mechanistic reasoning for all three top candidates argues against a plausible link. Safety information has also not yet been reviewed, so the candidate cannot move past the initial screening stage.
To proceed, the following is needed:
- The SAHPRA package insert (PI), to obtain warnings, contraindications and the approved indication
- Mechanism of action data for cupric chloride
- A literature and trial search that links copper to platelet function or platelet release disorders
- A route and formulation compatibility assessment, since Addaven is an infusion additive rather than a stand-alone product
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.